Base rate

Calendar effects: base rate from 126 out-of-sample tests

By Justin JaegerPublished Updated

Calendar effects were tested 126 times across 20 idea variants. 16% beat their benchmark in 2015–2026 after costs, with a median Sharpe difference of −0.93. Verdict as of 2026-11-01: dead end.

Sell in May, Santa rally: calendar tricks came last of every idea group we tested

Key numbers

MeasureValue
Tests126
Idea variants20
Beat benchmark15.9%
Median Sharpe vs benchmark−0.93
Looked good before 20151
… and held after100.0%
VerdictDead end

By asset class

Asset classTestsBeat benchmarkMedian Sharpe vs bmVerdict
US equities5317%−0.90Dead end
single stocks340%−1.47Dead end

Caveats

The 2015–2026 test window has been looked at many times during research, so we label it and do not call it a clean holdout. "Beat benchmark" compares each test with a fixed asset mix or buy-and-hold in the same window; a weak benchmark flatters the result. Many tests use US-listed ETFs.

Terms used: base rate, out-of-sample test, placebo test, dead end.

Before your next backtest

Let your AI check how ideas like yours did before it runs a single test. In our pilot, agents that checked first spent 1% of their backtests on known dead ends instead of 15%, and every backtest not wasted is time and tokens you keep. Cite this entry as ER-CAL-ALL, as of 2026-11-01.

Related evidence

Questions

Do calendar effects work?

Calendar effects were tested 126 times across 20 idea variants. 16% beat their benchmark in 2015–2026 after costs, with a median Sharpe difference of −0.93. Verdict as of 2026-11-01: dead end.

Is this investment advice?

No. These are research statistics, not recommendations.